Although some countries are beginning to reopen, the long-term impact of COVID-19 on cancer care continues to manifest. According to the IQVIA Institute Global Oncology Trends report, screenings remain at 11% to 23% below baseline levels. Diagnostics for screening and monitoring reached a deficit of 11 million in 2020. It is estimated that nearly 22 […]

Aptitude Health’s CORE events are designed to provide in-depth understanding of practice-specific patterns of care, disease-state treatment choices, and practice challenges and resource needs in different oncology and hematology indications. During the first 4 months of 2021, we conducted 8 different meetings among community oncologists and hematologists to gain insights into current practices in the […]

In May 2021, Aptitude Health held the first virtual CASES meeting in Europe, focusing on the treatment of adult patients with acute myeloid leukemia (AML). Leading European experts from Spain, Italy, and Germany, and a group of practicing hematologists from these countries discussed patient cases and exchanged reflections on experiences and regional variations regarding treatment […]

Clinical research has been greatly challenged in the wake of COVID-19, with 1773 US clinical trials reportedly suspended as of April 21, 2021. Pandemic-related restrictions on in-person visits created obstacles to trial enrollment, data collection, and intervention delivery. As reported in a recent opinion article by Dr Mary McDermott and Dr Anne Newman, even ongoing […]

As oncology professionals, we strive to improve survival and quality of life in all patients. June has several events to remind us of the rights of people of all colors (Juneteenth [June 19]—the anniversary of when the end of slavery in Texas was finally enforced), age (June 15—World Elder Abuse Awareness Day ), and gender […]

For some solid tumors, identification of genomic alterations susceptible to drug therapy has improved clinical outcomes. This has led to increased interest in next-generation sequencing (NGS) testing to identify patients who qualify for enrollment in biomarker-selected clinical trials. In the Michigan Oncology Sequencing Program (Mi-ONCOSEQ), a cohort study of 1015 patients who underwent integrative genomic […]

Interest in and access to telemedicine has gained momentum in recent years, especially during the COVID-19 pandemic. New diagnostic and communication technologies have greatly improved the capabilities and quality of available interventions. In fact, studies have demonstrated that telemedicine is equivalent to—or at times, achieves better outcomes than—in-person care, with improved cost-effectiveness, greater convenience, and […]

As reported previously, clinical trial enrollments decreased in the midst of the COVID-19 pandemic, primarily due to concerns about contagion. To examine the attitudes of cancer survivors toward trial participation, Dr Mark Fleury et al surveyed a large group of patients from the American Cancer Society Cancer Action Network’s Survivor Views panel in mid-2020. The […]

During the first 4 months of 2021, Aptitude Health conducted a number of business intelligence CORE meetings with Axess Network community oncologists to gain insights into current practice patterns for managing patients with acute myeloid leukemia (AML). These events are designed to increase understanding of patterns of care, disease-state treatment choices, practice challenges, and resource […]

Immune checkpoint inhibitors have demonstrated efficacy in multiple solid and hematologic malignancies over the past 10 years, and continue to redefine the course of therapy for many patients. They work by helping the immune system recognize and kill foreign targets and overcome the immunosuppressive tumor microenvironment. However, their use may be limited by adverse events […]